Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hospital Corporation of America Healthcare, Houston, Texas, USA.
Cancer Med. 2021 Dec;10(23):8387-8394. doi: 10.1002/cam4.4344. Epub 2021 Nov 9.
Patients with high-grade glioma (HGG) face unique challenges toward the end of life (EoL), given their aggressive trajectory and neurologic deterioration. Aggressiveness of medical care at EoL has been identified as an important quality metric for oncology patients. At this time, limited data exist around the nature of EoL care of patients with HGG.
Patients with HGG and palliative care (PC) referral seen between 2010 and 2015 were identified (N = 80). Of these, N = 52 met inclusion criteria. Random selections of patients with (1) HGG not referred to PC (n = 80), and (2) non-CNS cancers with PC referral (n = 80) were identified for comparison. A composite score of aggressiveness of medical care at EoL was calculated for each patient from predetermined variables. A time of eligibility for PC was defined for each patient when predetermined criteria based on symptom burden, functional status, and prognosis were met.
Among the patients analyzed with HGG referred to PC, 59.6% (N = 31) were referred as inpatients, and 53.8% (N = 28) were referred within the last 12 weeks of life. Patients with HGG had similar aggressiveness of care at EoL regardless of PC referral, and HGG patients had less aggressive care at EoL than patients with non-CNS cancers (p = 0.007). Care was more aggressive at EoL in HGG patients who received late versus early PC referrals (p = 0.012). Motor weakness at time of eligibility (OR = 2.55, p = 0.002) and more disease progressions (OR = 1.25, p = 0.043) were associated with less aggressive care at EoL.
Early clinical- and disease-related features predict the aggressiveness of medical care at EoL in patients with HGG. Formal PC consultation is used infrequently and suboptimally in patients with HGG. Our data suggest that the role of PC in improving EoL outcomes in HGG warrants further evaluation.
由于高级别神经胶质瘤(HGG)的侵袭性轨迹和神经恶化,患者在生命末期(EoL)面临独特的挑战。在 EoL 时医疗护理的积极性已被确定为肿瘤患者的一个重要质量指标。目前,关于 HGG 患者的 EoL 护理性质的数据有限。
在 2010 年至 2015 年间,确定了接受姑息治疗(PC)转诊的 HGG 患者(N=80)。其中,N=52 名符合纳入标准。随机选择未接受 PC 转诊的 HGG 患者(n=80)和接受 PC 转诊的非中枢神经系统癌症患者(n=80)进行比较。根据症状负担、功能状态和预后的预定标准,为每位患者定义了接受 PC 的资格时间。从预定变量计算 EoL 时医疗护理积极性的综合评分。
在接受 PC 转诊的 HGG 患者中,59.6%(N=31)为住院患者,53.8%(N=28)在生命的最后 12 周内转诊。无论是否接受 PC 转诊,HGG 患者的 EoL 护理积极性相似,HGG 患者的 EoL 护理积极性低于非中枢神经系统癌症患者(p=0.007)。接受晚期与早期 PC 转诊的 HGG 患者的 EoL 护理更具积极性(p=0.012)。在符合资格时的运动无力(OR=2.55,p=0.002)和更多疾病进展(OR=1.25,p=0.043)与 EoL 时的护理积极性较低相关。
早期临床和疾病相关特征预测了 HGG 患者 EoL 时医疗护理的积极性。姑息治疗的正式咨询在 HGG 患者中很少使用,且使用效果不理想。我们的数据表明,姑息治疗在改善 HGG 患者 EoL 结局方面的作用值得进一步评估。